WebBackground: Combination therapy with docetaxel and androgen deprivation therapy (ADT) prolongs overall survival (OS) in men with metastatic hormone-sensitive prostate cancer. We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age. Methods: We performed a post hoc analysis of the CHAARTED trial comparing … WebFeb 1, 2024 · New CHAARTED paper below, reflecting longer follow-up. "In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS)."
ASCO 2024: Treatment of mHSPC and Implications for …
WebWith the publication of CHAARTED, LATITUDE, and STAMPEDE, there are randomized data (1-3), and meta- ... of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2024;36:1080-7. 2. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2024;377:352-60. The primary objective of the E3805 study was to determine whether docetaxel therapy at the beginning of ADT for metastatic hormone-sensitive prostate cancer would result in longer overall survival than that with ADT alone. The study was designed in 2005 by the Eastern Cooperative Oncology Group … See more Regressions of metastatic prostate cancer were first documented in the 1940s and were achieved with surgical castration; subsequently, androgen-deprivation therapy (ADT) … See more Patients were enrolled by ECOG-ACRIN, the Southwest Oncology Group, the Alliance for Clinical Trials in Oncology, and NRG Oncology (a merged group that includes the National … See more PSA levels were measured at each scheduled visit. Imaging (computed tomography [CT] of the abdomen and pelvis, technetium-99m bone scanning, and radiography or … See more Patients were randomly assigned to ADT alone or to combination therapy with ADT plus docetaxel at a dose of 75 mg per square meter of body-surface area given every 3 weeks for six … See more la maison en tissu
CHAARTED Study: Conceptual Shift in Early Prostate …
WebJul 2, 2024 · The CHAARTED and LATITUDE trials demonstrated a prolonged overall survival (OS) for metastatic hormone-naïve prostate cancer (mHNPC) patients who … WebThe CHAARTED 2 trial led by Dr. Christos E. Kyriakopoulos, from the University of Wisconsin, will assess abiraterone +/- Cabazitaxel for extensive disease following docetaxel (trial design in figure 5): Agarwal … WebAug 21, 2024 · Analyses of clinical endpoints were completed by prior local therapy, prior docetaxel exposure, CHAARTED (NCT00309985)-defined disease volume, and LATITUDE (NCT01715285)-defined risk groups.... assassin aatrox